ClinicalTrials.gg
CompletedNCT04845854Updated Feb 14, 2023

Prevalence of Oral Side Effects Associated With Chemo and Radiotherapy for Treating Head and Neck Cancer

An observational study in Oral Complications of Chemotherapy and Head and Neck Radiation, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Cairo University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
294
Ages
20 Years to 70 Years
Sex
All
01

Study summary

A cross-sectional study will be conducted to report oral complications during chemo and radiotherapy treatment in case of patients diagnosed with head and neck cancer and the effect of theses oral side effects on patients' quality of life which will in turn allow the implication of preventive measures

Read the detailed description

the primary out come of this study is to report oral side effects associated with chemo and radiotherapy used for treating head and neck cancer .patient will be enrolled and data will be collected from the national institute of cancer in Egypt. this will be done through filling the modified ( Edmonton Symptom Assessment System) ESAS questionnaire used to asses different oral side effects in cancer patients. history taking and Clinical examination will be done for each patient enrolled in the study after obtaining their consent form by the main investigator. each and every oral manifestations will be measured by a specific scale . the secondary outcome is identified as the assessment of the effect of oral complications on patients' quality of life which will be determined through completing UW-QOL(University of Washington-Quality Of Life) questionnaire version 4.during the study, patient , treatment and tumor variable will be considered and documented .Data collected form the patient and or from medical records will be saved and tabulated on computer for back up and finally statistically analyzed. A power analysis was designed to have adequate power to apply a statistical test of the research question regarding the degree to which oral adverse events can prevail among patients receiving chemotherapy or radiotherapy. According to the results of Minhas, Sadia, et al. -in which prevalence of oral adverse events was (92.6%)- and by adopting a confidence interval of (95%), a margin of error of (3%) with finite population correction; the predicted sample size (n) was a total of (292) cases. Sample size calculation was performed using Epi info for windows version 7.2

02

Conditions studied

  • Oral Complications of Chemotherapy and Head and Neck Radiation
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,911 studies on the registry; 1,443 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

patients who are diagnosed with head and neck cancer and started their chemo and radiotherapy treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients after the first week of their treatment till the end of their treatment protocol and at their follow-up visits
  • patients who completed ESAS questioner
  • Male and female patients from 20 -70 years old who are diagnosed with head and neck cancer.

Exclusion criteria

Exclusion Criteria:

  • Patients who didn't start their treatment before the examination
  • Patients who refuse to participate in the study.
  • Patients with leukemia or blood cell cancers, infants and children
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
294 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. by ESAS questionnaire ,clinical examination of the patient

    questionnaire is answered by the patient

    Time frame: through study completion, an average of 1 year

  2. oral mucositis assessed by WHO(world Health Organization) scale, clinical examination

    grade(A)none , (I)mild ,(II)moderate (III)severe and( life threatening (B) 1 asymptomatic or mild pain,2moderate,3 severe,4 life threatening

    Time frame: through study completion, an average of 1 year

  3. xerostomia by CODs (Clinical oral dryness scale)

    questionnaire completed with added clinical examination scored from 1-3indicate mild dryness then 4-6 moderate dryness and 8-10 severe dryness

    Time frame: through study completion, an average of 1 year

  4. dysphagia by VHNSS Version 2.0 (Vanderbilt Head and Neck Cancer Symptom Survey)

    assess the severity of dysphagia by a questionnaire related to struggle during swallowing ,xerostomia, nutrition deficiency ,mucous secretion or taste changes ,mucositis and speech affection each scored from 0 (none) to 10 (severe).

    Time frame: through study completion, an average of 1 year

  5. pain assessed by numerical rating scale(NRS)

    from 0 indicating no pain to 10 being worst pain

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. quality of life assessment QOL-Version 4(Washington University Quality Of Life ) questionnaire

    questionnaire consists of 12 single question domains, these having between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response. The domains are pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder, taste, saliva, mood and anxiety

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • National Institute of Cancer in Egypt
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Feb 2022, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2021
First posted
Apr 15, 2021
StartActual
Oct 2, 2020
Primary completionActual
Feb 20, 2022
CompletionActual
Sep 3, 2022
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04845854
Lead sponsor
Cairo University
Responsible party
Dalia Mohamed abo el -fadel (post graduation student, Cairo University) — Principal investigator
First posted
Apr 15, 2021
Start date
Oct 2, 2020
Primary completion
Feb 20, 2022
Completion
Sep 3, 2022
Last update
Feb 14, 2023

Study contacts

dalia m abo el fadel, master
principal investigator · dentist at hospital specialized centers
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion